Waystar Targets Autonomous Revenue Cycle With AI, Automation Push at Investor Day

Waystar is positioning itself as a leader in autonomous healthcare revenue-cycle management by combining AI, automation and an end-to-end platform serving more than 32,000 clients, 1.5 million providers and roughly 60% of the U.S. patient population. The company’s 2026–2027 roadmap includes agentic AI for billing, coding and clinical documentation, denial prediction, automated claim resubmission and conversational analytics. Waystar plans to monetize these capabilities through premium features and new products targeting traditionally manual workflows. Waystar reaffirmed its long-term goals of low-double-digit revenue growth, adjusted EBITDA margins above 40% and approximately 70% free-cash-flow conversion, while prioritizing debt reduction, organic innovation, share repurchases and disciplined acquisitions. Can Waystar Still Stand Out Amidst Rising Competition? Waystar NASDAQ: WAY outlined its strategy to expand its healthcare revenue-cycle-management platform through artificial intelligence, automation and broader adoption of its end-to-end product suite during its inaugural Investor Day in San Antonio. Chief Executive Officer Matt Hawkins said the company’s strategy centers on category leadership in revenue cycle, a connected platform spanning pre-encounter through post-encounter workflows, and a longer-term vision for an “autonomous revenue cycle.” He said Waystar serves more than 1.5 million providers and over 32,000 clients, reaches about 60% of the U.S. patient population and now processes nearly 8.5 billion insurance transactions annually. “Every incremental transaction we process makes our network that much more robust,” Hawkins said, describing the company’s ability to use payment and workflow data to identify friction in billing, reimbursement and collections. AI strategy targets administrative complexity Hawkins said healthcare providers face rising operational pressure, including constrained margins, staffing turnover and payer-related denials. He characterized the revenue-cycle market as a more than $20 billion opportunity for Waystar’s current software offerings, with a further adjacent services opportunity that could expand the company’s addressable market to roughly twice that size. Waystar’s AI strategy is intended to reduce manual work, predict and prevent denials, automate selected tasks and shift revenue-cycle activity earlier in the patient journey. Hawkins said providers increasingly want to consume AI through trusted vendors rather than build and secure their own AI tools. He cited third-party research indicating that nearly 90% of providers prefer that approach. William Chan, Waystar’s Chief AI Officer and a co-founder of Iodine, said the company’s competitive position rests on four pillars: mission-critical workflow infrastructure, proprietary data, an extensively deployed network and revenue-cycle domain expertise. Iodine joined Waystar last year, adding clinical documentation, utilization management and revenue-capture capabilities to Waystar’s patient-access and claims-management products. “Waystar is the revenue cycle’s system of action,” Chan said. “This is where work gets done.” Brendan O’Connor, executive vice president of product management, said Waystar connects with more than 5,000 payers and integrates with more than 500 electronic health record and practice-management systems. Those connections, combined with transaction and payment data, allow the company to identify payer-specific reimbursement behavior and apply those insights directly into provider workflows, he said. Product roadmap includes agentic AI and new monetization paths Waystar highlighted several product initiat...